Introduction Dapagliflozin, a leading SGLT2 inhibitor, has evolved from a glucose-lowering agent to a cornerstone therapy for heart failure (HF). Built on pivotal trials like DAPA-HF and DELIVER, dapagliflozin now targets a broad spectrum of HF patients, including those without diabetes. A recent bibliometric analysis of literature from 2012 to 2024 maps the global research…